Somerset Therapeutics

What Somerset Therapeutics does

Somerset Therapeutics (operating as Somerset Pharma LLC) is a US-headquartered, privately held specialty generic pharmaceutical company founded in 2013 by Dr. Veerappan Subramanian and Dr. Ilango Subramanian. The company develops, manufactures, and commercializes bioequivalent generic medicines across five dosage-form categories — injectables, ophthalmics, oral solids, solutions, and nasal sprays — with a portfolio of more than 60 marketed products spanning anesthesia, cardiac care, ophthalmology, oncology, anti-infectives, and parenteral nutrition. Primary manufacturing is conducted at a USFDA-compliant facility in Bengaluru, India (compliant since 2013, with an EIR classified as Voluntary Action Indicated effective March 2024), supported by R&D facilities in Bengaluru and New Jersey and a wholly-owned R&D affiliate (Odin Pharmaceuticals LLC). The company has secured multiple Competitive Generic Therapy (CGT) designations providing 180-day exclusivity, including for Calcium Gluconate Injection, Atropine Sulfate Ophthalmic Solution, and Cupric Chloride Injection.

Somerset's revenue model is based on one-time sales of generic pharmaceutical products through a multi-channel US distribution network: direct enterprise field sales targeting hospitals, inpatient pharmacies, IDNs, and Home Infusion Centers; inside sales driving GPO contracts with state facilities and clinics; and wholesale distribution through AmerisourceBergen, Cardinal Health, McKesson, and M&D. The GTM motion is supported by IDN, Regional GPO, and independent client contract negotiations, with the company actively managing GPO-contracted product conversions. Pricing follows standard generic pharma unit pricing with a $500 minimum order, case-pack multiples, and standard payment terms (1.5% monthly interest on past-due invoices, 25% restocking fee). Marketing relies on industry conferences (NACDS TSE, HealthTrust University, NPPA), trade press releases, and an active business development outreach seeking US commercialization partners.

The company is operationally affiliated through three wholly-owned entities: Somerset Therapeutics LLC (US, holds IP rights and marketing authorizations), Somerset Therapeutics Ltd. (India, manufacturing), and Odin Pharmaceuticals LLC (US, R&D). It is expanding capacity with two new manufacturing buildings in Bengaluru and one in New Jersey to enter inhalation, topical, and lyophilized dosage forms. Leadership includes a Chief Growth Officer recognized with the Hatch Waxman Impact Case of the Year award and two Top 25 IP Leaders awards, and a Chief Operations and R&D Officer with prior leadership at Granules Pharmaceuticals and large generic manufacturers (Teva, Actavis, Watson, Par). Headcount stands at approximately 700 employees.

Name

Somerset Therapeutics

Legal name

Somerset Pharma LLC

Website

https://somersetpharma.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Somerset Therapeutics is a US-headquartered specialty generic pharmaceutical company that develops, manufactures at a USFDA-compliant facility in India, and commercializes more than 60 bioequivalent injectable, ophthalmic, oral solid, solution, and nasal spray products to US hospitals, IDNs, GPOs, and wholesalers.

Ownership category

akta.pro rank

Product category

Generic Sterile Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Ophthalmic & Otic Generics (HLAIABAF)

Keywords

• Generic injectable pharmaceuticals
• Sterile manufacturing services
• Ophthalmic drug products
• Hospital pharmaceutical supplies
• Bioequivalent generic medicines

Headquarters

HQ city

Somerset

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Infrastructure, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Product Sales: Revenue generated from manufacturing and supplying affordable generic medicines across injectables, ophthalmics, oral solids, solutions, and nasal sprays. Products sold to hospitals, pharmacies, and healthcare facilities through wholesalers and direct contracts.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Somerset Therapeutics is a US-based generic pharmaceutical company that manufactures and supplies affordable bioequivalent medicines across injectables, ophthalmics, oral solids, solutions, and nasal sprays. The company produces and sells sterile generic drugs through direct hospital sales, wholesale distribution, and GPO contracts, with USFDA-compliant manufacturing based in Bengaluru, India. Its portfolio spans more than 60 generic pharmaceutical products targeting hospitals, pharmacies, IDNs, and healthcare facilities in the US retail and hospital channels.

Product overview

Somerset Therapeutics is an American pharmaceutical company manufacturing and supplying affordable generic medicines across therapeutic segments including injectables, ophthalmics, oral solids, solutions, and nasal sprays. The portfolio consists of over 60 generic pharmaceutical products organized into five core categories: Injectables (such as Acetylcysteine Injection, Atropine Sulfate Injection, Calcium Gluconate Injection, Milrinone Lactate Injection, Naloxone Injection, Ropivacaine Hydrochloride Injection, and Sumatriptan Succinate Injection), Ophthalmics (including Atropine Sulfate Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution, Dorzolamide Ophthalmic Solution, Latanoprost Ophthalmic Solution, Moxifloxacin Ophthalmic Solution, and Timolol Maleate Ophthalmic Solution), Oral Solids (such as Cabergoline Tablets, Clonidine ER Tablets, Esomeprazole Magnesium Capsules, and Hydroxyurea Capsules), Solutions (including Acetylcysteine Solution, Nitrofurantoin Oral Suspension, and Valganciclovir Oral Solution), and Nasal Sprays (Dihydroergotamine Mesylate Nasal Spray). The company operates as a generic drug supplier with no unified software platform; products are bioequivalent alternatives to branded drugs manufactured at USFDA-compliant facilities in India.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Injectable Pharmaceuticals Sterile generic injectable drug products (vials, ampoules, pre-filled syringes) for hospitals, IDNs, and healthcare facilities, spanning anesthesia, cardiac care, antibiotics, electrolytes, sedation, and supportive care. The portfolio includes products such as Acetylcysteine Injection, Bortezomib Injection, Bupivacaine HCl Injection, Buprenorphine HCl Injection, Calcium Chloride Injection, Calcium Gluconate Injection, Cisatracurium Besylate Injection, Cupric Chloride Injection, Cyanocobalamin Injection, Dexamethasone Sodium Phosphate Injection, Dexmedetomidine Injection, Ephedrine Sulfate Injection, Glycopyrrolate Injection, Haloperidol Decanoate Injection, Lacosamide Injection, Levetiracetam in Sodium Chloride Injection, Methocarbamol Injection, Midazolam Injection, Milrinone Lactate Injection, Nalbuphine HCl Injection, Naloxone HCl Injection, Neostigmine Methylsulfate Injection, Nicardipine HCl Injection, Pemetrexed Injection, Phenylephrine HCl Injection, Potassium Phosphates Injection, Prochlorperazine Edisylate Injection, Ropivacaine HCl Injection, Sodium Acetate Injection, Sodium Nitroprusside Injection, Succinylcholine Chloride Injection, Sulfamethoxazole & Trimethoprim Injection, Sumatriptan Succinate Injection, Verapamil HCl Injection, Zinc Chloride Injection, and Zinc Sulfate Injection.
• Generic Ophthalmic Pharmaceuticals Sterile generic ophthalmic drug products (eye drops and solutions) for hospitals, ophthalmology clinics, and retail pharmacies. Indicated for glaucoma, allergic conjunctivitis, bacterial eye infections, pupil dilation, and topical ocular anesthesia. The portfolio includes Atropine Sulfate Ophthalmic Solution, Azelastine HCl Ophthalmic Solution, Bepotastine Besilate Ophthalmic Solution, Bimatoprost Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution, Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution, Dorzolamide HCl Ophthalmic Solution, Dorzolamide & Timolol Ophthalmic Solution, Epinastine HCl Ophthalmic Solution, Latanoprost Ophthalmic Solution, Moxifloxacin Ophthalmic Solution, Ofloxacin Ophthalmic Solution, Olopatadine HCl Ophthalmic Solution, Pilocarpine Ophthalmic Solution, Polymyxin B/Trimethoprim Ophthalmic Solution, Proparacaine HCl Ophthalmic Solution, Tetracaine HCl Ophthalmic Solution, Timolol Ophthalmic Solution, Timolol Maleate Ophthalmic Solution, Tobramycin Ophthalmic Solution, Travoprost Ophthalmic Solution, and Tropicamide Ophthalmic Solution.
• Generic Oral Solid Pharmaceuticals Generic oral solid dosage pharmaceutical products (tablets and capsules) for retail and hospital channels spanning gastroenterology, neurology, endocrinology, oncology supportive care, and infectious diseases. The portfolio includes Cabergoline Tablets, Clonidine HCl Extended-Release Tablets, Eltrombopag Tablets, Esomeprazole Magnesium Delayed-Release Capsules, Hydroxyurea Capsules, Prucalopride Tablets, and Rilpivirine Tablets.
• Generic Pharmaceutical Solutions Generic pharmaceutical liquid solutions and oral suspensions for hospitals, clinics, and retail pharmacy dispensing. Indicated for acetaminophen overdose, antiviral therapy, and urinary tract infections. The portfolio includes Acetylcysteine Solution USP, Valganciclovir Hydrochloride Oral Solution, and Nitrofurantoin Oral Suspension USP.
• Generic Nasal Spray Pharmaceuticals Generic nasal spray pharmaceutical products for acute migraine treatment, distributed via the same hospital, GPO, and wholesale channels as other Somerset products. The portfolio includes Dihydroergotamine Mesylate Nasal Spray.
• Ofloxacin Otic Solution Generic fluoroquinolone otic solution indicated for the treatment of bacterial ear infections, sold to hospitals and retail pharmacy channels as a standalone otic dosage form offering.

Quantifiable outcome

• EIR classified as VAI enabling more product approvals and increased capacity

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Torrent Pharmaceuticals LimitedminorOthers · 26 February 2026Torrent Pharmaceuticals Limited filed an Abbreviated New Drug Application (ANDA) seeking FDA approval to manufacture generic versions of Recorlev (levoketoconazole), triggering patent infringement lawsuit from Xeris Biopharma against both Somerset Therapeutics and Torrent.
• Somerset Therapeutics LLC, USAcoreStrategic or Co-development PartnerAffiliate entity that holds intellectual property rights and marketing authorizations for Somerset Pharma products. Serves as the label on products, ensuring compliance with regulatory requirements in the US market.
• Somerset Therapeutics Ltd., IndiacoreStrategic or Co-development PartnerManufacturing facility in India that plays a crucial role in production and supply of Somerset Pharma products. USFDA compliant since 2013, enables cost-effective manufacturing.
• Odin Pharmaceuticals LLC, USAcoreTechnology or IntegrationResearch and development facility that supports all R&D efforts undertaken by Somerset Pharma, including formulation development and advanced pharmaceutical technologies.
• Healthcare Partners and CollaboratorscoreChannel Partner/ Reseller/ DistributorCompany actively seeks partners interested in leveraging capabilities to commercialize products in the United States. Strengths in regulatory, quality, intellectual property, commercialization and sales enable synergies with potential collaborators.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Hikma Pharmaceuticals: Hikma is a leading generic injectable manufacturer with a broad hospital-focused portfolio including sterile injectables, ophthalmics, and complex generics — directly comparable to Somerset's product mix and customer base of hospitals and IDNs.
• Eugia Pharma (Aurobindo): Eugia is Aurobindo's specialty injectables business producing sterile injectables and oncology products for the US market. It directly overlaps with Somerset's injectable portfolio and US GPO/hospital channel strategy.
• Amphastar Pharmaceuticals: Amphastar specializes in injectable and intranasal generic pharmaceuticals, including complex generics and proprietary drug delivery. It is a comparable US-focused injectable generics competitor.
• Sagent Pharmaceuticals: Sagent is a US-focused specialty generic injectable company serving hospitals and GPOs with a portfolio that closely mirrors Somerset's hospital injectable and anti-infective product lines.
• Gland Pharma: Gland Pharma (owned by Fosun) is an India-based sterile injectables manufacturer with USFDA-approved facilities supplying the US market — directly comparable to Somerset's Bengaluru manufacturing model and injectable portfolio.
• AuroMedics Pharma USA: AuroMedics is Aurobindo's US generic injectables subsidiary supplying hospitals and wholesalers with a broad sterile injectable portfolio, closely comparable to Somerset in product mix and distribution model.

Broad incumbents

• Fresenius Kabi: Fresenius Kabi is a major global player in generic injectable pharmaceuticals, infusion solutions, and clinical nutrition — competing with Somerset in TPN-related injectables and broader hospital injectables.
• Dr. Reddy's Laboratories: Dr. Reddy's is a major India-based generic pharmaceutical company with significant sterile injectable and ophthalmic operations in the US market, including complex generics and biosimilars — overlapping with Somerset's portfolio and channel approach.
• Baxter International: Baxter is a global leader in injectable pharmaceuticals and IV solutions, with broad overlap in hospital injectables, TPN, and generic sterile products — though much larger and more diversified than Somerset.
• Lupin Pharmaceuticals: Lupin is a major India-based generic pharma company with US sterile injectable and ophthalmic operations, overlapping with Somerset's product portfolio and India manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Somerset Therapeutics